Cardiovascular · Topic 5 of 48

Chronic Coronary Disease & Stable Angina

Cardiovascular · stable ischemic heart disease

Chronic Coronary Disease & Stable Angina

Prevent events with aspirin, a high-intensity statin and risk-factor control; treat angina with a beta-blocker or CCB; revascularize when angina persists.

Key numbers

Maximally tolerated high-intensity statinLDL-C < 55 mg/dL

Treat blood pressure to below 130/80BP < 130/80

Long-term beta-blocker only with specific indicationsLVEF ≤ 50%

01 · GiveLow-dose aspirin for every patient

Give low-dose aspirin (75–81 mg daily) indefinitely to every patient with chronic coronary disease; clopidogrel 75 mg daily is the alternative when aspirin is not tolerated.

02 · GiveMaximally tolerated high-intensity statin

Give every patient a maximally tolerated high-intensity statin (atorvastatin 40–80 mg, rosuvastatin 20–40 mg); add ezetimibe, a PCSK9 inhibitor or bempedoic acid for LDL-C < 55 mg/dL (very high risk), otherwise < 70.

03 · GiveBeta-blocker or CCB first-line

First-line antianginal therapy is a beta-blocker or a calcium channel blocker; add a long-acting nitrate or ranolazine if angina persists, and give everyone sublingual nitroglycerin for attacks.

Diagnosis & monitoring

Work-up

Treat blood pressure to below 130/80Treat hypertension in chronic coronary disease to a target below 130/80 mmHg; even mild hypertension increases cardiac workload.

Management

Orders

Exercise ECG needs exercise and readable ECG must knowExercise ECG requires a patient who can exercise and an interpretable resting ECG; choose stress imaging (pharmacologic if unable to exercise) with LBBB, paced rhythm, WPW, LVH, digoxin or ≥ 0.5 mm resting ST depression.

CCTA first for younger intermediate-probability patientsCCTA accurately excludes obstructive CAD and is a first-line test for stable chest pain under age 65 with intermediate–high probability; use it cautiously with heart rate over 65, arrhythmia, kidney impairment or pregnancy.

Nitrate-free interval of 8–10 hours dailyLong-acting nitrates cause tolerance: schedule a daily nitrate-free interval of 8–10 hours for nitroglycerin patches (about 12 hours for isosorbide dinitrate), usually overnight.

Ranolazine for refractory angina; watch QTRanolazine (500–1000 mg twice daily) is added when angina persists on other antianginals; it can prolong the QT interval and causes dizziness, headache and constipation.

SGLT2 inhibitor or GLP-1 RA for diabetesPatients with chronic coronary disease and type 2 diabetes should receive an SGLT2 inhibitor or GLP-1 receptor agonist; selected patients without diabetes (e.g., with heart failure) also benefit.

Refer to cardiac rehabilitationRefer eligible patients to cardiac rehabilitation, which lowers morbidity and mortality, and prescribe regular aerobic and resistance exercise for everyone without contraindications.

Red flags & don'ts

Avoid harm

Avoid short-acting nifedipine; no verapamil in HFrEF avoidShort-acting nifedipine causes hypotension and reflex tachycardia and raises mortality; non-dihydropyridine CCBs (verapamil, diltiazem) are avoided with LV systolic dysfunction, where amlodipine is the safest CCB.

The rules

Know these

Revascularize for angina despite medical therapy must knowRevascularize for lifestyle-limiting angina despite guideline-directed medical therapy when stenoses are suitable; survival benefit is limited to high-risk anatomy such as left main or 3-vessel disease with poor LV function.

Long-term beta-blocker only with specific indicationsLong-term beta-blocker therapy does not improve outcomes unless there was an MI in the past year, LVEF ≤ 50% or another primary indication; otherwise it is used only for angina.

No routine repeat stress testing when stableDo not repeat anatomic or ischemia testing on a schedule when clinical and functional status are unchanged; retest for new or worsening symptoms.

Stable angina or unstable angina?

Commonly confused

Trigger	Predictable exertion or emotional stress
Duration and relief	Minutes; relieved by rest or nitroglycerin
Pattern	Unchanged
Next step	Outpatient testing and medical therapy

Teach & follow up

Patient education

Sublingual nitroglycerin 0.3–0.6 mg, up to 3Teach sublingual nitroglycerin 0.3–0.6 mg at onset or before exertion, repeated every 5 minutes up to 3 doses; relief usually comes within 1.5–3 minutes. Store tablets sealed in a light-resistant glass container.

More detail

Reference

Show 8 reference facts

In vasospastic angina, avoid beta-blockers other than labetalol or carvedilol — unopposed alpha stimulation can worsen spasm; calcium channel blockers and nitrates are the treatment.

Ivabradine slows the sinus rate without reducing contractility; it is an option for angina in sinus rhythm at 70 beats/min or more when beta-blockers cannot be used.

For complex multivessel disease needing revascularization (e.g., SYNTAX score over 33), CABG is reasonable over PCI to improve survival — see Coronary Revascularization.

Fish oil, omega-3 and vitamin supplements are not recommended because they do not reduce cardiovascular events.

Low-dose colchicine may be added for secondary prevention in chronic coronary disease.

Smoking cessation cuts all-cause mortality by about 36% after 2 years; e-cigarettes are not first-line cessation therapy because long-term safety data are lacking.

Give influenza, COVID-19 and pneumococcal vaccines to patients with chronic coronary disease.

On medical therapy, stable angina carries about a 3–4% annual risk of death or MI; poor exercise capacity, severe angina, diabetes and reduced GFR raise it.

Pearl

Medications prevent the heart attack; revascularization mostly relieves the angina — except in left main or high-risk multivessel disease.

Sources · Merck Manual Professional — Stable Angina · ACC — 2023 Multisociety Guideline for Managing Chronic Coronary Disease: Key Perspectives (Virani SS et al., Circulation 2023;148:e9–e119) · Merck Manual Professional — Medications for Acute Coronary Syndromes (table: medications for coronary artery disease) · Merck Manual Professional — Dyslipidemia · ACC — 2021 ACC/AHA/SCAI Coronary Revascularization Guideline: Key Perspectives · AFP Practice Guidelines — Chest Pain Evaluation: Updated Guidelines From the AHA/ACC (2023) · Merck Manual Professional — Unstable Angina · Merck Manual Professional — Chest Pain · Guideline Central — 2026 ACC/AHA Management of Dyslipidemia Guideline: key highlights · EBSCO EBM Focus — Top takeaways from the updated ACC/AHA guideline on management of dyslipidemia (2026) · Starter sheet built from the verified AGACNP fact map (facts reviewed 2026-10-15).